Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2024 Jun 12

PMID 38865670

Authors

Carlos Torrado

Ruth Plummer

Timothy A Yap

Affiliations

Soon will be listed here.

Abstract

Biomarker-based patient selection and rational combinations show promise in expanding the use of PARP inhibitors.

References

Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim Y, Gris-Oliver A . RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018; 29(5):1203-1210. PMC: 5961353. DOI: 10.1093/annonc/mdy099. View

Tung N, Garber J . PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer. 2022; 8(1):47. PMC: 8993852. DOI: 10.1038/s41523-022-00411-3. View

Ngoi N, Leo E, OConnor M, Yap T . Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors. Cancer J. 2021; 27(6):521-528. DOI: 10.1097/PPO.0000000000000556. View

Fennell D, Porter C, Lester J, Danson S, Blackhall F, Nicolson M . Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine. 2022; 52:101595. PMC: 9386392. DOI: 10.1016/j.eclinm.2022.101595. View

Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernandez A, Viaplana C . Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Res. 2022; 82(8):1646-1657. PMC: 7612637. DOI: 10.1158/0008-5472.CAN-21-2409. View

Yap T, Hamilton E, Bauer T, Dumbrava E, Jeselsohn R, Enke A . Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO Precis Oncol. 2022; 6:e2100456. PMC: 8865521. DOI: 10.1200/PO.21.00456. View

Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M . Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26):2495-2505. DOI: 10.1056/NEJMoa1810858. View

Schlam-Babayov S, Bensimon A, Harel M, Geiger T, Aebersold R, Ziv Y . Phosphoproteomics reveals novel modes of function and inter-relationships among PIKKs in response to genotoxic stress. EMBO J. 2020; 40(2):e104400. PMC: 7809795. DOI: 10.15252/embj.2020104400. View

Leichman L, Groshen S, ONeil B, Messersmith W, Berlin J, Chan E . Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist. 2016; 21(2):172-7. PMC: 4746089. DOI: 10.1634/theoncologist.2015-0319. View

10.

Antoniou A, Pharoah P, Narod S, Risch H, Eyfjord J, Hopper J . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72(5):1117-30. PMC: 1180265. DOI: 10.1086/375033. View

11.

Stover E, Konstantinopoulos P, Matulonis U, Swisher E . Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clin Cancer Res. 2016; 22(23):5651-5660. DOI: 10.1158/1078-0432.CCR-16-0247. View

12.

Coleman R, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106):1949-1961. PMC: 5901715. DOI: 10.1016/S0140-6736(17)32440-6. View

13.

Yap T, Plummer R, Azad N, Helleday T . The DNA Damaging Revolution: PARP Inhibitors and Beyond. Am Soc Clin Oncol Educ Book. 2019; 39:185-195. DOI: 10.1200/EDBK_238473. View

14.

Bhamidipati D, Haro-Silerio J, Yap T, Ngoi N . PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023; 129(6):904-916. PMC: 10491787. DOI: 10.1038/s41416-023-02326-7. View

15.

Jonsson P, Bandlamudi C, Cheng M, Srinivasan P, Chavan S, Friedman N . Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019; 571(7766):576-579. PMC: 7048239. DOI: 10.1038/s41586-019-1382-1. View

16.

Yap T, Sandhu S, Carden C, de Bono J . Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin. 2011; 61(1):31-49. DOI: 10.3322/caac.20095. View

17.

Litton J, Hurvitz S, Mina L, Rugo H, Lee K, Goncalves A . Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020; 31(11):1526-1535. PMC: 10649377. DOI: 10.1016/j.annonc.2020.08.2098. View

18.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall M . Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019; 381(4):317-327. PMC: 6810605. DOI: 10.1056/NEJMoa1903387. View

19.

OMalley D, Krivak T, Kabil N, Munley J, Moore K . PARP Inhibitors in Ovarian Cancer: A Review. Target Oncol. 2023; 18(4):471-503. PMC: 10344972. DOI: 10.1007/s11523-023-00970-w. View

20.

Agarwal N, Azad A, Carles J, Fay A, Matsubara N, Heinrich D . Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10398):291-303. DOI: 10.1016/S0140-6736(23)01055-3. View